PIK3CG and adrenal cortex carcinoma: Due to the unavailability of PIK75 for clinical trial, another PI3K inhibitor, BGT226, which was clinically available and demonstrated a comparable synergistic efficacy with STA9090, was validated in the ACC cell lines.